SPP1 and lung carcinoma: Consistent with these reports, the clinical value of circulating osteopontin was recently confirmed in the management of non-small-cell lung cancer [62] and in newly diagnosed primary lung cancer patients, in whom increased levels of osteopontin were significantly linked to worse survival [31].